TITLE:
The anti-inflammatory effect of picroside II and the optimizing of therapeutic dose and time window in cerebral ischemic injury in rats
AUTHORS:
Li Zhao, Xiaodan Li, Tingting Wang, Yunliang Guo, Fangfang Pang, Cuicui Chang
KEYWORDS:
Picroside II; Therapeutic Dose; Time Window; Cerebral Ischemia; AQP4; MMP9; COX-2; Rats
JOURNAL NAME:
Modern Research in Inflammation,
Vol.2 No.3,
July
17,
2013
ABSTRACT: The
aim is to optimize the anti-inflammatory effect and the therapeutic dose and
time window of picrosede II by orthogonal test in cerebral ischemic injury in rats. The forebrain ischemia models
were established by bilateral common carotid artery occlusion (BCCAO) methods
in 30 Wistar rats. The successful
models were randomly divided into sixteen groups according to orthogonal
experimental design and treated by injecting
picroside II intraperitoneally at different ischemic time with different
dose. The concentrations of aquaporins 4 (AQP4), matrix metalloproteinases9
(MMP9) and cyclooxygenase 2 (COX2) in serum and brain tissue were determined by
enzyme linked immunosorbent assay to evaluate the therapeutic effect of
picroside II in cerebral ischemic injury. The best therapeutic time window and
dose of picroside II in cerebral ischemic injury were 1) ischemia 2.0 h with 20
mg/kg and 1.5 h with 20 mg/kg body weight according to the concentration of
AQP4 in serum and brain tissue; 2) ischemia 1.5 h with 20 mg/kg and ischemia
2.0 h with 20 mg/kg according to the concentrations of MMP9 in serum and brain
tissue; and 3) ischemia 1.5 h with 10 mg/kg and ischemia 1.5 h with 20 mg/kg according
to the concentrations of COX2 in serum and brain tissue respectively. According
to the principle of the lowest therapeutic dose with the longest time window, the optimized therapeutic dose and time window were injecting picroside II intraperitoneally with 10 - 20 mg/kg
body weight at ischemia 1.5 - 2.0 h in cerebral ischemic injury.